Rundu Co., Ltd. (002923.SZ) plans to pay 2 yuan for 10 shares to be deducted from interest on May 31
Rundu Co., Ltd. (002923.SZ) announced that the company's 2023 equity distribution plan: to all shareholders every 10...
Express News | Rundu Co., Ltd.: Prices of sartan APIs are expected to gradually stabilize
Express News | Rundu Co., Ltd.: A number of the company's small molecule compounds are using synthetic biology technology for process development
The synthetic biology concept bottomed out and rebounded. In 7 days and 4, Xintiandi surged more than 10%, while Rundu Co., Ltd., Fujilai, Tuoxin Pharmaceuticals, and Rhine Biotech followed suit.
The synthetic biology concept bottomed out and rebounded. In 7 days and 4, Xintiandi surged more than 10%, while Rundu Co., Ltd., Fujilai, Tuoxin Pharmaceuticals, and Rhine Biotech followed suit.
Rundu Co., Ltd. (002923.SZ): Net profit of 29.055,800 yuan in the first quarter decreased by 28.14% year-on-year
On April 26, Ge Longhui Co., Ltd. (002923.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 306 million yuan, down 14.82% year on year; net profit attributable to shareholders of listed companies was 29.0558 million yuan, down 28.14% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 255.725 million yuan, down 29.80% year on year; basic earnings per share were 0.09 yuan.
Rundu Co., Ltd. (002923.SZ): The product application range covers various fields such as peptic ulcer, hypertension, surgical anesthesia, antipyretic analgesia, anti-infective, and diabetes
Gelonghui, April 9 | Rundu Co., Ltd. (002923.SZ) said on the investor interactive platform that the company is a modern technology-based pharmaceutical enterprise integrating drug R&D, production and sales. Its main business is R&D, production and sales of chemical preparations, chemical raw materials, pharmaceutical intermediates. The product application range covers peptic ulcers, hypertension, surgical anesthesia, antipyretic analgesia, anti-infective, diabetes, etc. Nicotine is a new business field that the company has expanded in recent years, and has now formed a certain level of commercial sales. The company will actively adjust the strategic plan according to the market environment to seek more opportunities for commercial cooperation
Rundu Co., Ltd. (002923.SZ): Reganosheng obtained a notice of approval for the marketing application of chemical raw materials
Gelonghui, March 29 | Rundu Co., Ltd. (002923.SZ) announced that the company recently received the approval and issuance of Reganosin (hereinafter referred to as “this product”) “Notice of Approval of the Marketing Application for Chemical Ingredients” from the China Drug Administration. This product is an important part of the company's industrial chain in the field of cardiac stress medication. With the application and promotion of cardiac stress drugs in the field of coronary heart disease diagnosis, it is expected to benefit more patients.
Express News | Rundu Co., Ltd.: The nicotine business is developing steadily, and the current production capacity can meet sales needs
Rundu Co., Ltd. (002923) First Coverage Report: Integrated Development of API Formulations to Help Take Off
Key points of the report: The coronary heart disease diagnosis market space is vast, and there is room to improve the penetration rate of nuclide myocardial perfusion imaging. The number of patients with coronary heart disease in China is huge, exceeding 11 million. It is expected that the number of patients will continue in the future as the population ages
Rundu Co., Ltd. (002923.SZ): Not involved in artificial intelligence-assisted new drug development
Gelonghui, March 21丨Some investors asked Rundu Co., Ltd. (002923.SZ) on the investor interactive platform, “Does the company use artificial intelligence to assist in the development of new drugs?” The company replied that the company has not yet involved artificial intelligence-assisted research and development of new drugs.
Rundu Co., Ltd. (002923.SZ): The existing production capacity of the alkaloid (nicotine) project can meet sales needs
Gelonghui March 8 | Rundu Co., Ltd. (002923.SZ) held an investor relationship on March 6, 2024. Regarding “What is the progress of the alkaloid (nicotine) business now? How much production capacity does the company have in this area? What position is it in the industry?” The company replied that the alkaloid (nicotine) business is developing normally. The current production capacity of the company's alkaloid (nicotine) project can meet sales needs. Alkaloids can be used in various fields such as medicine, pesticides, e-cigarettes, oral cigarettes, nicotine patches, etc., and have a wide range of applications. At present, the company has formed a certain level of commercial sales and is in accordance with local market entry mechanisms
Rundu Co., Ltd. (002923.SZ): Overseas revenue is mainly generated from the sales business of APIs and intermediates
Gelonghui March 8 | Rundu Co., Ltd. (002923.SZ) held an investor relationship on March 6, 2024. Regarding “What part of the business is the company's overseas revenue mainly?” The company replied that the company's overseas revenue was mainly generated from the sales business of APIs and intermediates.
Rundu Co., Ltd. (002923.SZ): Normethorphine hydrochloride injection is currently still in the registration and approval stage with the State Drug Administration
Gelonghui March 8, 丨 Rundu Co., Ltd. (002923.SZ) held an investor relationship on March 6, 2024 to discuss “Is this normethacidine hydrochloride injection product interested in expanding overseas markets?” The company replied that the normethorphine hydrochloride injection is currently still in the registration and approval stage with the State Drug Administration. In the future, based on domestic market development and sales, the possibility of expanding overseas markets is not ruled out.
Express News | Rundu Co., Ltd.: Application for marketing license for normethacrine hydrochloride injection was accepted
Express News | Rundu Co., Ltd. received a registration certificate for olmesartan ester hydrochlorothiazide tablets
Rundu Co., Ltd. (002923.SZ): No studies have been conducted on the application of normethamine hydrochloride in the treatment and prevention of Alzheimer's disease
Gelonghui, Feb. 29丨Rundu Co., Ltd. (002923.SZ) said on an interactive platform that the company has not studied the application of normethacin hydrochloride in the treatment and prevention of Alzheimer's disease.
Express News | Rundu Co., Ltd.: Levobupivacaine hydrochloride injection (5ml: 37.5mg) passed the generic drug consistency evaluation
Express News | Rundu Co., Ltd.: Voriconazole dry suspension obtained drug registration certificate
Express News | Rundu Co., Ltd.: Application for marketing registration of normethrin hydrochloride as an API accepted
Rundu Co., Ltd. (002923.SZ) issued a pre-reduction. Net profit for 2023 is expected to drop 49% to 56% year-on-year
Rundu Co., Ltd. (002923.SZ) announced its 2023 annual results forecast. It is expected to be owned by listed company shareholders for the whole year...
No Data